Here is a new PD-1 immunotherapy combination trial about to open. It alllows MSS-CRC patients. It combines a "anti-CSF1R" drug called "AMG 820" with an anti-PD-1 drug. It uses the same strategy as the "FPA008" trial previously posted (so just search for that name or look in my signature line hyperlink) and a few months ahead of it in development. The anti-CSF1R is intended to removed immunosuppresive "tumor associated macrophages" from the tumor to make it "hotter" and more prone to T-Cell attack after PD-1 inhibition. Trial locations have not been announced yet but it will be a big trial - so there will be multiple locations nationwide
https://clinicaltrials.gov/ct2/show/NCT ... 529&rank=1
Cheers,
-DK